NEW YORK, Oct. 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Prime Therapeutics, Inc. FPRX, National Health Investors, Inc. NHI, Starwood Property Trust, Inc. STWD, Biohaven Pharmaceutical Holding Company Ltd. BHVN, Aclaris Therapeutics, Inc. ACRS, and Mitek Systems, Inc. MITK, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
FPRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=FPRX
NHI DOWNLOAD: http://Fundamental-Markets.com/register/?so=NHI
STWD DOWNLOAD: http://Fundamental-Markets.com/register/?so=STWD
BHVN DOWNLOAD: http://Fundamental-Markets.com/register/?so=BHVN
ACRS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACRS
MITK DOWNLOAD: http://Fundamental-Markets.com/register/?so=MITK
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Five Prime Therapeutics, Inc. FPRX, National Health Investors, Inc. NHI, Starwood Property Trust, Inc. STWD, Biohaven Pharmaceutical Holding Company Ltd. BHVN, Aclaris Therapeutics, Inc. ACRS, and Mitek Systems, Inc. MITK on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 8th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
FIVE PRIME THERAPEUTICS, INC. (FPRX) REPORT OVERVIEW
Five Prime Therapeutics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Five Prime Therapeutics reported revenue of $7.58MM vs $7.82MM (down 3.09%) and analysts estimated basic earnings per share -$0.99 vs -$1.58. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Five Prime Therapeutics reported revenue of $39.51MM vs $30.69MM (up 28.73%) and analysts estimated basic earnings per share -$5.38 vs -$2.44. Analysts expect earnings to be released on November 5th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$1.54. The estimated EPS forecast for the next fiscal year is -$4.70 and is expected to report on February 26th, 2019.
To read the full Five Prime Therapeutics, Inc. (FPRX) report, download it here: http://Fundamental-Markets.com/register/?so=FPRX
-----------------------------------------
NATIONAL HEALTH INVESTORS, INC. (NHI) REPORT OVERVIEW
National Health Investors' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, National Health Investors reported revenue of $72.96MM vs $69.83MM (up 4.48%) and analysts estimated basic earnings per share $0.91 vs $0.93 (down 2.15%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, National Health Investors reported revenue of $278.66MM vs $248.46MM (up 12.15%) and analysts estimated basic earnings per share $3.90 vs $3.88 (up 0.52%). Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $1.37. The estimated EPS forecast for the next fiscal year is $5.68 and is expected to report on February 15th, 2019.
To read the full National Health Investors, Inc. (NHI) report, download it here: http://Fundamental-Markets.com/register/?so=NHI
-----------------------------------------
STARWOOD PROPERTY TRUST, INC. (STWD) REPORT OVERVIEW
Starwood Property Trust, Inc.'s Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Starwood Property Trust, Inc. reported revenue of $269.56MM vs $211.57MM (up 27.41%) and analysts estimated basic earnings per share $0.41 vs $0.45 (down 8.89%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Starwood Property Trust, Inc. reported revenue of $879.89MM vs $784.67MM (up 12.14%) and analysts estimated basic earnings per share $1.53 vs $1.52 (up 0.66%). Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.64. The estimated EPS forecast for the next fiscal year is $2.18 and is expected to report on February 27th, 2019.
To read the full Starwood Property Trust, Inc. (STWD) report, download it here: http://Fundamental-Markets.com/register/?so=STWD
-----------------------------------------
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (BHVN) REPORT OVERVIEW
Biohaven Pharmaceutical Holding's Recent Financial Performance
Analysts expect earnings to be released on November 13th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$1.19. The estimated EPS forecast for the next fiscal year is -$5.40 and is expected to report on March 5th, 2019.
To read the full Biohaven Pharmaceutical Holding Company Ltd. (BHVN) report, download it here: http://Fundamental-Markets.com/register/?so=BHVN
-----------------------------------------
ACLARIS THERAPEUTICS, INC. (ACRS) REPORT OVERVIEW
Aclaris Therapeutics' Recent Financial Performance
Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.63. The estimated EPS forecast for the next fiscal year is -$3.96 and is expected to report on March 11th, 2019.
To read the full Aclaris Therapeutics, Inc. (ACRS) report, download it here: http://Fundamental-Markets.com/register/?so=ACRS
-----------------------------------------
MITEK SYSTEMS, INC. (MITK) REPORT OVERVIEW
Mitek's Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, Mitek reported revenue of $16.11MM vs $11.80MM (up 36.54%) and analysts estimated basic earnings per share -$0.08 vs $0.02. For the twelve months ended September 30th, 2017 vs September 30th, 2016, Mitek reported revenue of $45.39MM vs $34.70MM (up 30.80%) and analysts estimated basic earnings per share $0.43 vs $0.06 (up 616.67%). Analysts expect earnings to be released on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $0.18 and is expected to report on November 6th, 2018.
To read the full Mitek Systems, Inc. (MITK) report, download it here: http://Fundamental-Markets.com/register/?so=MITK
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
